A study in the journal Viruses validates the use of SeptiCyte® RAPID as a tool to measure disease severity in COVID-19 patients, in comparison to a reference method based on chest computed tomography (CT) imaging.
A new study in Scientific Reports, a journal in the Nature portfolio, validates the use of SeptiCyte® RAPID as a triaging tool for COVID-19 patients requiring hospitalization and potentially ICU care.
At the Association for Molecular Pathology annual meeting and exposition this week, Immunexpress launched a rapid molecular diagnostic test that could enable ruling in or ruling out sepsis in one hour.
DocWire News spoke with Dr. Rollie Carlson, CEO of Immunexpress, to learn more about this cutting-edge technology, and how it can quickly and accurately detect sepsis, and lead to faster treatment.
In this Q&A, Immunexpress Chief Executive Officer Dr Rolland Carlson and Chief Scientific Officer Dr Richard Brandon discuss key aspects for molecular diagnostic discovery and development platforms, including how to best leverage microarray and next-generation sequencing (NGS) tools.
SeptiCyte® RAPID EDTA blood compatible cartridges were recently launched in the European market, representing a significant development milestone for the identification of pathogens associated with sepsis. This press release and the associated blog posts explore the significance of this development.
This article from Technology Networks includes an interview with Rolland Carlson, PhD, the CEO of Immunexpress. Rolland describes the paradigm shift in sepsis diagnosis as well as the specifics of how SeptiCyte® RAPID provides a faster and accurate diagnosis, allowing physicians to quickly rule-in or rule-out sepsis.
Learn more about the process of getting the lab test for sepsis, SeptiCyte® RAPID, cleared by the FDA. This article from Med Device Online also includes tips for obtaining a 510(k) FDA Clearance for other medical use products.
At the 32nd ECCMID, Immunexpress and collaborators at Hospital Foch, France, shared research demonstrating that SeptiCyte® RAPID sepsis test can distinguish between COVID-19 patients showing higher extents of lung damage as defined by lung CT scans from those with a milder presentation.
In this DNA Weekly interview, Immunexpress CEO Dr. Rollie Carlson, discusses why the company is tackling sepsis, explains the challenge of diagnosing sepsis, and details how SeptiCyte® RAPID helps. He also discusses how SeptiCyte® RAPID allows hospital systems to improve their sepsis management quality scores.
Often difficult to diagnosis, sepsis remains a leading cause of morbidity and mortality among intensive care unit (ICU) patients. SeptiCyte® RAPID is the first FDA-cleared sepsis diagnostic to differentiate sepsis from non-infectious systemic inflammation to aid in rapid sepsis diagnosis within approximately one hour.
This Medical Device Network article highlights our FDA-cleared sepsis diagnostic SeptiCyte® RAPID. The fast sepsis test addresses “a critically unmet need in the ICU,” said Immunexpress Chief Medical Officer, Dr. Roy Davis. SeptiCyte® technology aids physicians in distinguishing sepsis from -infection-negative (SIRS) systemic inflammation in critically ill patients.
In this interview with 10 News Brisbane, Dr. Adam Irwin, physician, and senior lecturer of pediatric infectious disease at the University of Queensland, details how deadly a sepsis diagnosis can be for children. Richard Brandon, Chief Scientific Officer of Immunexpress, shares the development of a one-hour sepsis test, SeptiCyte® RAPID, that is awaiting Australian regulatory approval.
SeptiCyte® RAPID is a sepsis test that uses peripheral blood gene expression biomarkers to provide accurate sepsis diagnosis in patients presenting with clinical signs of systemic inflammation. Data was presented detailing the superior performance of SeptiCyte® RAPID in differentiating sepsis from non-infectious inflammatory responses at the 2021 IDWeek Conference.